Head-to head comparison of anterior nares and nasopharyngeal swabs for SARS-CoV-2 antigen detection in a community drive-through test centre in the UK

Ana I Cubas Atienzar[1*], Rachel L Byrne[1], Ghaith Aljayyoussi[1], Konstantina Kontogianni[1], Daisy Bengey[1], Karina Clerkin[1], Mathew McIntyre[1], Jahanara Wardale[1], Christopher T Williams[1], CONDOR steering group, Richard Body[2], Camille Escadafal[3], Emily R Adams[1,4].

[1] Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK

[2] Manchester University NHS Foundation Trust, UK

[3] FIND, Geneva, Switzerland

[4] Global Access Diagnostics, Bedfordshire, UK

* Corresponding author Ana I Cubas Atienzar Ana.CubasAtienzar@lstmed.ac.uk

Running title: Anterior nares or NP swabs for SARS-CoV-2 RDTs

Corresponding authors: Ana I Cubas Atienzar, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK. Ana.cubasatienzar@lstmed.ac.uk

+44 (0) 151 705 3187

Keywords: SARS-CoV-2, COVID-19, Nasal swabs, nasopharyngeal swabs, antigen detection, RDT, LFA, head-to-head comparison.

Abstract:

Objective: To conduct a head-to-head diagnostic accuracy evaluation of professionally taken anterior nares (AN) and nasopharyngeal (NP) swabs for SARS-CoV-2 antigen detection using rapid diagnostic tests (Ag-RDT).

Methods: NP swabs for SARS-CoV-2 reverse transcription quantitative polymerase chain reaction (RT-qPCR) testing and paired AN and NP swabs for the antigen detection were collected from symptomatic participants enrolled at a community drive-through COVID-19 test centre in Liverpool. Two Ag-RDT brands were evaluated: Sure-Status (PMC, India) and Biocredit (RapiGEN, South Korea). The visual read out of the Ag-RDT test band was quantitative scored and the 50% and 95% limit of detection (LoD) of both Ag-RDT brands using AN and NP swabs was calculated using a probabilistic logistic regression model.

Results: A total of 604 participants were recruited of which 241 (40.3%) were SARS-CoV-2 positive by RT-qPCR. Sensitivity and specificity of AN swabs was equivalent to the obtained with NP swabs: 83.2% (75.2-89.4%) and 98.8% (96.5-99.6%) utilising NP swabs and 84.0% (76.2-90.1%) and 99.2% (97.0-99.8%) with AN swabs for Sure-Status and; 81.2% (73.1-87.7%) and 99.0% (94.7-86.5%) with NP swabs and 79.5% (71.3-86.3%) and 100% (96.5-100%) with AN swabs for Biocredit. The agreement of the AN and NP swabs was high for both brands with an inter-rater relatability (κ) of 0.918 and 0.833 for Sure-Status and Biocredit, respectively. The overall 50% LoD and 95% LoD was 0.9-2.4 × 10^4 and 3.0-3.2 × 10^8 RNA copies/mL for NP swabs and 0.3- 1.1 x 10^5 and 0.7-7.9 x 10^7 RNA copies/mL and for AN swabs with no significant difference on LoD for any of the swabs types or test brands. Quantitative read-out of test line intensity was more often higher when using NP swabs with significantly higher scores for both Ag-RDT brands.

Conclusions: the diagnostic accuracy of the two SARS-CoV-2 Ag-RDTs brands evaluated in this study was equivalent using AN swabs than NP swabs. However, test line intensity was lower when using AN swabs which could influence negatively the interpretation of the Ag-RDT results for lay users. Studies on Ag-RDT self-interpretation using AN and NP swabs are needed to ensure accurate test use in the wider community.

Abstract word count: 345

59 **Introduction**

60 To meet the immense diagnostic demand of the COVID-19 pandemic, the development of
61 rapid diagnostic tests for the detection of SARS-CoV-2 antigens (Ag-RDTs) became a priority
62 [1]. Nasopharyngeal (NP) swabs are considered the standard of care for SARS-CoV-2
63 detection[2] and thus the majority of Ag-RDT kits are developed for NP swabs exclusively [1].
64 However, the use of anterior nasal (AN) swabs has been increasing as a less invasive
65 alternative to promote access to testing in the community and facilitate mass testing
66 programmes particularly in the UK [3].

67 For Ag-RDTs, studies on Ag-RDTs comparing sensitivity on AN swabs and NP swabs are very
68 limited, with only two reported studies performed on the same Ag-RDT brand, Standard-Q
69 (SD Biosensor, Inc., Korea), one study on professional taken swabs [6] and another in self-
70 taken [7]. Sensitivity obtained with AN swabs was comparable (although 3% to 5% lower) than
71 with NP swabs sensitivity but neither of the swab types fulfilled WHO target product profile
72 (TPP) standards in any of the two studies [8]. AN swabs are considered accurate and clinically
73 acceptable alternatives to NP swabs in outpatient settings for SARS-CoV-2 reverse
74 transcription polymerase chain reaction (RT-PCR) testing [4]. However, an in depth
75 metanalysis on SARS-CoV-2 RT-PCR testing found that anterior nares specimens were 12%-
76 18% less sensitive than NP swabs [5].

77 The aim of this study was to perform a head-to-head evaluation on two World Health
78 Organisation (WHO) approved or under assessment for Emergency Use listing (WHO-EUL)
79 SARS-CoV-2 Ag-RDT brands marketed for AN and NP swabs: Sure-Status COVID-19 Antigen
80 Card Test (Premier Medical Corporation, India) and Biocredit COVID-19 Antigen Test
81 (RapiGEN, South Korea) respectively. This study is of particular interest in the UK as the use

82 of home Ag-RDTs on AN swabs has been integral to combatting the spread of COVID-19 during
83 the pandemic [3],as on the 1st of April 2022 free national RT-PCR COVID-19 testing was
84 suspended, with the purchase of Ag-RDTs using AN-swabs online or in pharmacies the only
85 approach to access COVID-19 testing in a non-clinical setting.

86 **Methods**

87 **Clinical evaluation**

88 This was a prospective evaluation of consecutive participants enrolled at a community
89 National Health Service (NHS) drive-through COVID-19 test centre located at the Liverpool
90 John Lennon Airport. Two Ag-RDT brands were evaluated; Sure-Status COVID-19 Antigen Card
91 Test (Premier Medical Corporation India) and Biocredit COVID-19 Antigen Test (RapiGEN,
92 South Korea) referred as Sure-Status and Biocredit thereafter. The study progressed until at
93 least 100 Ag-RDT positives using AN swabs in line with WHOs requirements for evaluation of
94 alternative sample type [10].

95 All adults over the age of 18 who attended the drive-through test centre with symptoms of
96 COVID-19 were asked to participate in the study. The symptoms included fever, cough,
97 shortness of breath, tight chest, chest pain, runny nose, sore throat, anosmia, ageusia,
98 headache, vomiting, abdominal pain, diarrhoea, confusion, rush, or tiredness. Participants
99 were recruited under the Facilitating Accelerated COVID-19 Diagnostics (FALCON) study using
100 verbal consent. Ethical approval was obtained from the National Research Ethics Service and
101 the Health Research Authority (IRAS ID:28422, clinical trial ID: NCT04408170).

102 Swabs were collected following the same process with the NP swab collected first in one
103 nostril and placed in Universal Transport Media (UTM) (Copan Diagnostics Inc, Italy) for the

104 reference RT-qPCR test. This was followed by the collection of two swabs to evaluate the Ag-
105 RDTs, first an NP swab in the other nostril and finally a AN swab in both nostrils following the
106 manufacturer's instructions for use (IFU). Samples were given a unique identification code
107 and transported within cooler bags to the Liverpool School of Tropical Medicine (LSTM) where
108 samples were processed in category level 3 (CL3) containment laboratory upon arrival.

109 Sure-Status and Biocredit Ag-RDTs were carried out following their instructions for use (IFU).
110 The protocol for both Ag-RDT was the same when using AN and NP swabs. Results were read
111 by two operators, blinded to one another and if a discrepant result occurred, a third operator
112 acted as a tiebreaker. The visual read out of the Ag-RDT test band was scored on a quantitative
113 scale from 1 (weak positive) - 10 (strong positive). Ag-RDT results were classified as invalid
114 when the control line was absent.

115 RNA was extracted using the QIAamp® 96 Virus QIAcube® HT kit (Qiagen, Germany) on the
116 QIAcube® (Qiagen, Germany) and screened using TaqPath COVID-19 (ThermoFisher, UK) on
117 the QuantStudio 5™ thermocycler (ThermoFisher, UK), an internal extraction control was
118 incorporated before the lysis stage, as recommended by the manufacturer. SARS-CoV-2 RT-
119 qPCR result was considered (1) positive if any two of the three SARS-CoV-2 target genes (N
120 gene, ORF1ab and S gene) amplified with cycle threshold (Ct) ≤ 40, (2) indeterminate if only
121 one SARS-CoV-2 gene amplified and (3) negative if the internal extraction control amplified
122 and the SARS-CoV-2 target genes did not. Samples with invalid RT-qPCR results (no
123 amplification of the internal extraction control) were re-extracted and re-run once. Viral loads
124 in UTM swabs were measured with a ten-fold serial dilution standard curve of quantified
125 specific in vitro-transcribed RNA using five replicates for each standard curve point [11].

126 **Statistical Analysis**

127 Sensitivity, specificity, positive predicted value (PPV) and negative predictive values (NPV)
128 were calculated with 95% confidence intervals (CIs) by comparing the Ag-RDT results to the
129 RT-qPCR, as the reference standard. Sub-analyses of diagnostic performance were performed
130 by swab type (AN and NP), Ct-value ranges, onset of symptoms and vaccination status using
131 nonparametric statistics. The level of agreement between AN and NP swabs was determined
132 using Cohen's kappa (κ) [10]. The correlation between test line intensity and viral loads were
133 measured by Person correlation, coefficient (r_P) [12] and to further analyse Ag-RDT
134 sensitivities, we used logistic regression, with RNA copy numbers of the RT-qPCR NP swab and
135 swab type (AN and NP) as independent variables and test outcomes as the dependent
136 variable, yielding detection probabilities for each viral load level. Statistical analyses were
137 performed using SPSS V.28.0, Epi Info V3.01 and R scripts. Statistical significance was set at P
138 < 0.05.

139 **Results**

140

141 Participant demographics

142 A total of 604 participants were recruited for this study, 372 recruited between August and
143 October 2021 were enrolled for the Sure-Status Ag-RDT evaluation and 232 recruited
144 between December 2021 and March 2022 were enrolled for the Biocredit Ag-RDT evaluation.
145 Details of the demographics of the population of study are found in Table 1. Our study
146 population had a mean age of 43 years (range 18-81, interquartile range [IQR] 33.0-50.0), 348
147 (58%) were female and 566 were British (94%), with the remaining 36 participants being of
148 other ethnic groups (n = 14), white background (n = 9), Asian (n = 8), mix white and black
149 backgrounds (n = 2) and Arab (n = 1). Three hundred and fourteen participants of the 372

150 enrolled for the Sure-Status evaluation (84.4%) and 217 participants of the 232 recruited for
151 Biocredit (93.5%) received complete SARS-CoV-2 vaccination (2 doses). Additionally, 143 of
152 the participants enrolled from December 2021 (61.6%) for the Biocredit evaluation received
153 a third dose as part of the UK booster roll out [13]. All participants were symptomatic with a
154 median onset of symptoms of 2 days (IQR 1-3). The most common symptoms were cough
155 (387, 64.3%), sore throat (232, 38.5%), headache (203, 33.7%), fever (160, 26.6%), body aches
156 (80, 13.3%) and runny nose (80, 13.3%) (Table 1).

157 Overall, 241 participants (40.3%, CI95% 36.3-44.4%) were SARS-CoV-2 positive by RT-qPCR, 6
158 had indeterminate RT-qPCR results and the remaining 355 were negative. Participants with
159 indeterminate RT-qPCR results were excluded from further analysis.

160 RT-qPCR positivity was significantly higher ($p<0.05$) among the participants enrolled for the
161 Biocredit evaluation cohort (53.7%, CI95% 47-60.4%) during December 2021 and March 2022
162 which coincided with the Omicron wave in the UK [14] than among the participants enrolled
163 between August and October 2021 (32.1%, CI95% 27.4-37.1%) when Delta was the dominant
164 SARS-CoV-2 variant.

165 Diagnostic evaluation

166 *Sure Status*

167 The overall sensitivity and specificity for the Sure-Status Ag-RDT compared to RT-qPCR was
168 83.2% (CI95% 75.2-89.4%) and 98.8% (CI95% 96.5-99.6%) utilising NP swabs and 84.0% (CI95%
169 76.2-90.1%) and 99.2% (CI95% 97.0-99.8%) with AN swabs. For individuals with Cts < 25, the
170 sensitivity was 91.8% (CI95% 84.5-96.4%) and 93.8% (CI95% 87.2-97.7%) for NP and AN-swabs
171 respectively. Seven Ag-RDTs gave invalid results, one NP swab (0.03%) sample and six AN

172 swab samples (1.6%). Participants with invalid Ag-RDTs results were excluded from further
173 analysis. Four SARS-CoV-2 positive cases were detected by NP only (3.4%) and six cases were
174 detected by AN only (5.0%) but this discrepancy on sensitivity between swab types was not
175 significant (*P* = 0.43). The percentage of agreement of NP and AN swab using Sure-Status was
176 96.7% (95% CI 94.3-98.3%) and inter-rater reliability was almost perfect (κ = 0.918). Inter-
177 rater reliability was strong for both NP (κ = 0.871) and AN (κ = 0.852) swabs when compared
178 to RT-qPCR.

179 *Biocredit*

180 For the Biocredit Ag-RDT the sensitivity and specificity were 81.2% (CI95%73.1-87.7%) and
181 99.0% (CI95%94.7-86.5%) with NP swabs and 79.5% (CI95%71.3-86.3%) and 100%
182 (CI95%96.5-100%) with AN sampling compared to RT-qPCR. Sensitivity was 92.2% (CI95%84.6-
183 96.8%) and 95.5% (CI95%89.0-98.8%) using NP and AN swabs among participants with Ct <
184 25. Ten SARS-CoV-2 positive cases were detected solely by NP (8.2%) and eight cases were
185 detected only by AN (6.6%) but no significance on sensitivity was observed between NP and
186 AN swabs for this brand of Ag-RDTs either (*P* = 0.43). The percentage of agreement of NP and
187 AN swab for Biocredit was 91.6% (95% CI 87.2-94.9%) and inter-rater reliability was strong (κ
188 = 0.833). Inter-rater reliability was moderate for both NP (κ = 0.790) and AN (κ = 0.782)
189 sampling compared to RT-qPCR. Diagnostic accuracy for both Sure-Status and Biocredit is
190 displayed in Table 2.

191 *Head to head comparison of Sure Status and Biocredit*

192 rWe report nosignificant difference in the diagnostic accuracy among participants with
193 symptoms irrespective of days since onset, or vaccination status for all Ag-RDTs and swabbing
194 combination (all *P* values > 0.05). Both Biocredit and Sure-Status Ag-RDTs using both swab

195 types had better sensitivities on detecting SARS-CoV-2 antigens on individuals with Ct values
196 < 25 than >30 (*P* = 0.029 in NP and *P* = 0.047 in AN for Sure-Status and *P* = 0.018 and *P* = 0.001
197 for Biocredit).

198 The RNA copy numbers per mL (RNA copies/mL) of RT-PCR NP swabs was calculated and
199 statistically higher viral loads were obtained for the Sure-Status cohort than Biocredit (Fig 1)
200 measured by Kruskal–Wallis (*P*= 0.006). We determined the 50% and 95% limits of detection
201 (LoD) for both Ag-RDT and swab types based on a logistic regression model (Fig 2). For Sure-
202 Status, the RNA copies/mL for 50% LoD and 95% LoD were 2.4×10^4 and 3.16×10^8 for NP
203 specimen and 3.4×10^4 and 7.94×10^7 for AN swabs. For Biocredit, the RNA copies/mL for
204 LoD50 and LoD95 were 9.12×10^3 and 3.02×10^8 for NP specimen and 1.12×10^5 and $6.76 \times$
205 10^6 for AN swabs. Although the LoD95 was better for AN swabs for both Ag-RDT brands (3.98
206 for Sure-Status and 44.67 for Biocredit), there was no statistical difference on LODs neither
207 by swab type and Ag-RDT brand (all *P* values > 0.05).

208 *Quantitative read-out analysis*

209 Quantitative read-out in paired positive AN and NP was more often higher for the NP (40
210 instances higher on NP and four higher on AN in Sure-Status; and 35 instances higher on NP
211 and 12 higher on AN in Biocredit) and gave significantly higher scores for both Ag-RDT, Sure-
212 Status (*P* = 0.007) and Biocredit (*P* = 0.013) (Figure 1) measured by Kruskal–Wallis.
213 Additionally, test lines scores were analysed by RNA copies/mL and these had a positive
214 correlation. For Biocredit, strong correlation using AN swabs (r_P = 0.727) but moderate using
215 NP swabs (r_P = 0.591). For Sure-Status, both swab types had a moderate correlation to viral
216 loads (NP swab r_P = 0.614 and AN swab r_P = 0.661).

217 **DISCUSSION**

218 This is the first diagnostic clinical evaluation of Sure-Status Ag-RDT and results have shown a
219 satisfactory performance for both AN and NP swabs fulfilling the sensitivity (≥80%) and
220 specificity (≥97%) outlined in the target product profile (TPP) WHO standards [8]. For Biocredit
221 Ag-RDT, there are five studies to date that have evaluated the performance of NP swabs
222 reporting varied sensitivities from 52% to 85% [15]. In this study we report a higher sensitivity
223 (81.2% ,CI95%73.1-87.7%) and specificity (99.0% ,CI95%94.7-86.5%) of the Biocredit Ag-RDT
224 fulfilled the WHO standards using NP swab but underperformed in the sensitivity (79.5%,
225 CI95% 71.3-86.3%) criteria when using AN.

226 Results presented here demonstrate that AN swabs are equivalent to NP swabs for SARS-CoV-
227 2 Ag-RDT testing giving comparable sensitivities, 50% LoD and 95% LoD for both Ag-RDTs
228 brands evaluated here. Our results supports previous findings where AN and NP swabs were
229 compared for the Ag-RDT Standard-Q (SD Biosensor, Inc., Korea) in Lesotho [6], but we
230 reported a higher sensitivity compared to the 67.3% and 70.2% for AN and NP swabs
231 previously described [6]. Studies on RT-qPCR have found lower sensitivity using AN swabs
232 compared to NP swabs consistently [5]. However, the difference in sensitivity was only
233 significant for patients with viral loads < 10^3 copies/mL [16] and this threshold is not relevant
234 to Ag-RDTs of which the limit of detection ranges between 10^4- 10^8 RNA copies/mL in swabs
235 [11].

236 Quantitative assessment of the test line scores showed that test line intensity was
237 significantly higher on NP swabs than AN swabs. The line intensity is an important component
238 of home testing as studies have shown fainter lines are more difficult to interpret for a lay
239 person, likely due to lower signal intensity [17]. In an user experience home based study,
240 77.1% of the cases that the participants interpreted wrongly as negative being positive, were

241 weak and moderate positives while only 22.9% were strong positives [17]. The significantly
242 lower intensity of the AN swab compared to NP swab is likely attributed to the differences of
243 SARS-CoV-2 viral loads in the respiratory tract. Studies have found lower viral loads on AN
244 swabs compared to NP swabs [16]. Statistical analysis supported this hypothesis where a
245 positive correlation between viral loads and Ag-RDT test line scores was shownFurther
246 implementation studies on Ag-RDT test results interpretation by patients or within a home
247 testing setting are urgently needed to drive self-testing to scale.

248 This study has several strengths, the use of standardised sampling methods, independent
249 blinded readers, robust statistical analysis, quantitative assessment of Ag-RDT test line results
250 and the evaluation of one approved WHO-EUL Ag-RDT test brands (Sure-Status) and under
251 review (Biocredit). Qualifying it to have high global public health relevance [18].

252 The main limitation of this study is that the AN swabs were always taken last. The order of
253 sample collection could have negatively biased the results obtained for AN swabs caused by
254 a possible sample depletion. However, in the two studies that compared Ag-RDT using AN
255 swabs, the AN swab was collected first and our reported sensitivity and specificity for AN
256 swabs are greater than the previous studies [6,7]. Further, studies on RT-qPCR found lower
257 sensitivity using AN swabs compared to NP swabs [5], even when AN swabs were collected
258 first [15,18,19]. Thereby it is unlikely that the order of the swabs impacted sample availability
259 for AN and NP sampling.

260 In conclusion, this study demonstrates the sensitivity of two SARS-CoV-2 Ag-RDTs using AN-
261 sampling are comparable to that of NP-sampling. AN-sampling can be performed with less
262 training, reduces patient discomfort, and enables scaling up of antigen testing strategies.
263 Test line intensity however is lower when using AN swabs which could influence negatively

264 the interpretation of the Ag-RDT results. Additional studies on Ag-RDTs using AN swabs on
265 self-interpretation by a lay person are needed and further education around how to
266 interpret a positive Ag-RDT to the wider community.

267 **Acknowledgements**

268 The work was funded by the Foundation of Innovative Diagnostics (FIND)

269 **REFERENCES**

270 1 FIND. SARS-CoV-2 diagnostic pipeline. https://www.finddx.org/covid-19/pipeline/

271 2 Center of Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and
272 Testing Clinical Specimens for COVID-19. May 22. 2020.

273 3 GOV.UK. New campaign urges public to get tested twice a week. Published Online First:
274 2021.https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-
275 twice-a-week

276 4 Péré H, Péré H, Péré H, *et al.* Nasal swab sampling for SARS-CoV-2: A convenient alternative
277 in times of nasopharyngeal swab shortage. J. Clin. Microbiol. 2020. doi:10.1128/JCM.00721-
278 20

279 5 Zhou Y, OLeary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial
280 detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-Analysis. PLoS One.
281 2021. doi:10.1371/journal.pone.0254559

282 6 Labhardt, Niklaus D González Fernández L, Katende, Bulemba Muhairwe J, Bresser M, *et al.*
283 Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid
284 antigen testing in Lesotho. *medRxiv* Published Online First: 2022.
285 doi:10.1101/2021.12.29.21268505

286 7 Lindner AK, Nikolai O, Kausch F, *et al.* Head-to-head comparison of SARS-CoV-2 antigen-

287 detecting rapid test with self-collected anterior nasal swab versus professional-collected
288 nasopharyngeal swab. *Eur Respir J*
289 2020;**57**:2003961.http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03961-2020

290 8 (WHO) WHO, R&D Blue Print WH (HQ). Target product profiles for priority diagnostics to
291 support response to the COVID-19 pandemic v.1.0. Published Online First:
292 2020.https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-
293 priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1

294 9 GOV.UK. People with a positive lateral flow test no longer required to take confirmatory PCR
295 test. Published Online First: 2021.https://www.gov.uk/government/news/people-with-a-
296 positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test

297 10 World Health Organization (WHO). Prequalification Teams D. Instructions and requirements
298 for Emergency Use Listing (EUL) Submission: In vitro diagnostics detecting SARS-CoV-2 nucleic
299 acid or antigen.
300 https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6
301 _NAT-Ag.pdf

302 11 Cubas-Atienzar, Ana I., Kontogianni K, Edwards T, *et al.* Limit of detection in different
303 matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. *Sci*
304 *Rep* 2021;**11**:1–8. doi:https://doi.org/10.1038/s41598-021-97489-9

305 12 Schober P, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. *Anesth*
306 *Analg* Published Online First: 2018. doi:10.1213/ANE.0000000000002864

307 13 GOV.UK. Vaccinations in the UK. Coronavirus UK.
308 2022.https://coronavirus.data.gov.uk/details/vaccinations

309 14 Mahase E. Covid-19: Is the UK heading for another omicron wave? *BMJ* 2022;**376**.
310 doi:https://doi.org/10.1136/bmj.o738

311 15 Brümmer LE, Katzenschlager S, Gaeddert M, *et al.* Accuracy of novel antigen rapid diagnostics
312 for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med. 2021.
313 doi:10.1371/journal.pmed.1003735

314 16 Callahan C, Lee R, Lee G, *et al.* Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral
315 Loads. *medRxiv* 2020.

316 17 Jing M, Bond R, Robertson LJ, *et al.* User experience of home-based AbC-19 SARS-CoV-2
317 antibody rapid lateral flow immunoassay test. *Sci Rep* 2022;**12**:1173. doi:10.1038/s41598-
318 022-05097-y

319 18 World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic — Emergency
320 Use Listing Procedure (EUL) open for IVDs. Prequalification Med. Prod. (IVDs, Med. Vaccines
321 Immun. Devices, Vector Control. https://extranet.who.int/pqweb/vitro-
322 diagnostics/coronavirus-disease-covid-19-pandemic-—-emergency-use-listing-procedure-eul-
323 open

324 19 Hanson KE, Barker AP, Hillyard DR, *et al.* Self-collected anterior nasal and saliva specimens
325 versus health care worker-collected nasopharyngeal swabs for the molecular detection of
326 SARS-CoV-2. *J Clin Microbiol* Published Online First: 2020. doi:10.1128/JCM.01824-20

327 20 Tu Y-P, Jennings R, Hart B, *et al.* Swabs Collected by Patients or Health Care Workers for
328 SARS-CoV-2 Testing. *N Engl J Med* Published Online First: 2020. doi:10.1056/nejmc2016321

329

330

331

332

333

334



335

336 **Figure 1.** Boxplot of the SARS-CoV-2 viral load distribution of the RT-qPCR NP swabs used as

337 reference standard for the participants enrolled for Sure-Status and Biocredit Ag-RDT evaluation.

338 The whiskers show the maximum and minimum values and the vertical line the median. Asterisks

339 indicate statistical significance between AN and NP swab types.

340

341

342



343

344 **Figure 2**. Limit of detection analyses of upper-respiratory samples positive by RT-qPCR for Sure-
345 Status and Biocredit using AN and NP swabs. The log10 RNA copies on the x axis were plotted
346 against a positive (1.0) or negative (0.0) Ag-RDT result on the y axis. Green (Sure-Status) and purple
347 (Biocredit) curves show logistic regressions of the viral load on the Ag-RDT result; vertical dashed
348 lines indicate log10 RNA copies subjected to the test at which 50% and 95% LoD of the samples are
349 expected positive based on the regression results. No significant differences were observed.

350

351



Figure 3. Boxplot of the scores of the test lines for both Ag-RDT Sure-Status and Biocredit using AN and NP swabs. The whiskers show the maximum and minimum values and the vertical line the median. Asterisks indicate statistical significance between AN and NP swab types.

365

366 **Table 1.** Demographics of the population of study for Sure-Status and Biocredit cohorts

	Sure-Status	Biocredit	All
Total	372	232	604
Age [mean (min-max), IQR]	43 (18-81), 33-53	43 (18-78), 33-51	43 (18-81), 33-52
Gender [%F, (n/N)] IQR]	57%, (211/372)	59%, (137/232)	58%, (348/602)
Triple vaccinated (n, %)	NA*	143 (61.6%)	143 (23.8%)
Double vaccinated (n, %)	314 (84.4%)	74 (40%)	388 (64.4%)
Partially vaccinated (n, %)	29 (7.8%)	4 (1.7%)	33 (5.5%)
Not vaccinated (n, %)	27 (7.3%)	10 (4.3%)	37 (6.2%)
Vaccination not disclosed (n, %)	2 (0.5)	1 (0.3%)	3 (0.5%)
Days symptoms onset [median (IQR); N]	2 (1-3), 371	2 (1-3), 232	2 (1-3), 601
Days 0-3 (n, %)	304, 81.7%	186, 80.2%	490, 81.1%
Days 4-7 (n, %)	56, 15.1%	41, 17.7%	97, 16.1%
Days 8+ (n, %)	10, 2.7%	5, 2.2%	15, 2.5%
RT-qPCR SARS-CoV-2 Positivity [%, (n/N)]	32.1%, (119/371)	53.7%, (122/227)	40.3% (241/598)
Symptom [total n (%), in RT-qPCR positive n (%)]			
Cough	248 (66.7%), 73 (61.3%)	139 (60.0%), 71 (58.2%)	387 (64.3%), 144 (60.0%)
Sore throat	129 (34.7%), 34 (28.6%)	103 (44.4%), 56 (45.9%)	232 (38.5%), 90 (37.4%)
Headache	123 (33.1%), 57 (47.9%)	80 (34.5%), 45 (36.9%)	203 (33.7%), 102 (42.3%)
Fever	106 (28.5%), 30 (25.2%)	54 (23.3%), 28 (22.9%)	160 (26.6%), 58 (24.1%)
Body aches	41 (11.0%), 21 (17.7%)	39 (16.8%), 29 (23.8%)	80 (13.3%), 51 (21.2%)
Runny nose	39 (13.2%), 20 (16.8%)	41 (17.7%), 31 (25.4%)	80 (13.3%), 51 (21.2%)
Loss taste	48 (12.9%), 19 (16.0%)	19 (8.2%), 10 (8.2%)	67 (11.1%), 29 (12.0%)
Loss smell	29 (7.8%), 9 (7.6%)	14 (6.0%), 7 (5.7%)	43 (7.1%), 16 (6.6%)
Chest pain	18 (4.8%),7 (5.9%)	12 (5.2%), 8 (6.6%)	30 (5.0%), 15 (6.2%)
Fatigue	13 (3.5%), 4 (3.4)	17 (7.3%), 10 (8.2%)	30, (5.0%), 14 (5.8%)
Shortness of breath/tight chest	13 (3.5%), 3 (2.5%)	9 (3.9%), 5 (4.1%)	22 (3.6%), 15 (6.2%)
Vomiting	11 (3%), 5 (4.2%)	2 (8.6%), 2 (1.6%)	13 (2.2%), 7 (2.9%)
Diarrhoea	9 (2.4%), 3 (2.5%)	3 (13%), 3 (2.5%)	12 (2.0%), 6 (2.5%)
Abdominal pain	6 (1.6%), 3 (2.5%)	1 (0.4%), 1 (0.8%)	7 (1.2%), 4 (1.7%)
Rash	3 (0.8%), 0 (0.0%)	1 (0.4%), 1 (0.8%)	4 (0.6%), 1 (0.4%)
Confusion	1 (0.3%), 0 (0.0%)	0 (0%)	1 (0.2%), 0 (0%)
Other	159 (42.7%), 68 (57.4%)	134 (57.8%), 85 (69.7%)	293 (48.7%), 153 (63.5%)

367 *Participants were enrolled before booster rolled out in the UK

368

369

370

371

372 **Table 2**. Clinical sensitivity and specificity of Sure-Status and Biocredit using NP and Nasal Swab

All Ct values	TP	FP	TN	FN	Sensitivity	Specificity	NPV	PPV
Sure-Status	200	5	494	38	83.9 (78.3-88.1)	99.0 (97.7-99.7)	92.7(90.5-94.4)	97.6 (94.3-98.9)
NP swab	99	2	249	20	83.2 (75.2-89.4)	98.8 (96.5-99.6)	91.7 (88.4-94.2)	97.1 (91.44-99.03)
AN swab	101	2	245	18	84.0 (76.2-90.1)	99.2 (97.0-99.8)	92.8 (89.5-95.1)	98.0 (92.62-99.5)
Biocredit	196	1	209	48	80.3 (74.8-85.1)	99.1 (95.0-99.9)	81.3(77.2-84.9)	99.5 (96.5-100)
NP swab	99	1	104	23	81.2 (73.1-87.7)	99.0 (94.7-86.5)	81.9 (73.99-85.2)	99.0 (93.4-99.9)
AN swab	97	0	105	25	79.5 (71.3-86.3)	100 (96.5-100)	80.8 (74.8-85.6)	100 (100-100)
All NP	198	4	353	43	82.2 (76.7-86.8)	98.9 (97.2-99.7)	89.1 (86.2-91.5)	98.0 (94.9-99.2)
All AN	198	2	350	43	82.2 (76.7-86.8)	99.4 (97.9-99.9)	89.1 (86.2-91.5)	99.0 (96.1-99.8)

373